For the third quarter of 2026, analysts expect Aldeyra Therapeutics to report a consensus revenue of $2.50 million and an EPS loss of -$0.11, with the stock currently trading at $0.56 against a significantly higher average price target of $5.50.
The primary focus for investors is the regulatory status of reproxalap, specifically the pending Formal Dispute Resolution Request (FDRR) following a third FDA rejection in March 2026.
Aldeyra expects to meet with the Office of New Drugs in late 2026 to appeal the agency's conclusion regarding the totality of clinical evidence for dry eye disease.
Management recently updated its financial guidance to extend the company's cash runway into 2029, providing a vital cushion for these ongoing regulatory efforts and the continued development of its RASP modulator platform.